Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now

Uveal Melanoma Drug Pipeline — PatSnap Eureka

Uveal Melanoma Drug Pipeline — PatSnap Eureka
Uveal Melanoma Drug Pipeline

Tebentafusp, PKC Inhibitors & Liver-Directed Therapies in Uveal Melanoma

The uveal melanoma pipeline has entered a pivotal era: the first FDA-approved therapy in metastatic UM, renewed PKC pathway inhibition strategies, and escalating liver-directed approaches that reflect the organ-specific biology of this disease. Explore the full innovation landscape with PatSnap Eureka.

Pipeline at a Glance
Uveal Melanoma Drug Pipeline by Development Stage: FDA Approved 1 modality (Tebentafusp), Phase Ib/II Clinical 2 modalities (PKC combinations, ICI), Preclinical 6 modalities (Gq/11 inhibitors, HDAC, ASO, YAP/TAZ, IRS-1/2, CDK4/6+MET), Clinical retrospective 1 modality (Liver-directed) Horizontal bar chart showing the distribution of uveal melanoma therapeutic modalities across development stages, derived from patent and literature analysis via PatSnap Eureka. Tebentafusp is the sole FDA-approved agent; the majority of pipeline activity is preclinical. FDA Approved 1 Phase Ib/II 2 Clinical 1 Preclinical 6 0 1 2 3 4 5 6 Number of therapeutic modalities
Source: PatSnap Eureka · Patent & Literature Dataset · 2016–2024
~50%
of UM patients develop distant metastases
>90%
of UM tumors carry GNAQ or GNA11 mutations
17.8 mo
median OS with liver-directed therapy (Cohort 3, n=730)
87%
rash rate in tebentafusp Phase 2 (n=127 patients)
Therapeutic Modalities

Key Approaches in the Uveal Melanoma Drug Pipeline

From the first FDA-approved bispecific T-cell engager to preclinical kinase combinations, the UM pipeline spans ten distinct therapeutic strategies targeting the disease's unique molecular architecture.

FDA Approved

Tebentafusp (ImmTAC Bispecific)

Developed by Immunocore Limited, tebentafusp is a soluble TCR fused to an anti-CD3 scFv. The TCR domain engages gp100 peptide presented by HLA-A*02:01 on tumor cells, while the anti-CD3 arm recruits polyclonal CD3+ T cells to kill targeted cells. A phase III trial demonstrated improved overall survival versus pembrolizumab, ipilimumab, or dacarbazine in first-line HLA-A*02:01-positive metastatic UM.

HLA-A*02:01 restriction limits eligibility to ~40–50% of Western patients
Phase Ib/II Clinical

Protein Kinase C (PKC) Inhibitors

Mechanistically justified by near-universal GNAQ/GNA11 mutations, PKC inhibitors sotrastaurin (AEB071) and darovasertib (IDE196) are the most patent- and literature-supported targeted therapy in this dataset. Single-agent activity is limited; the field has moved toward combinations with MDM2 inhibitors, PI3K inhibitors, and mTORC1/2 inhibitors. A life sciences IP analysis reveals Novartis holds inactive IL-jurisdiction patents covering MDM2 + PKC combinations.

PKC + MDM2 and PKC + PI3K combinations in clinical evaluation
Clinical (Retrospective)

Liver-Directed Local Therapies

Over 90% of metastatic UM cases involve hepatic metastases, making liver-directed modalities (chemoembolization, surgical excision, isolated hepatic perfusion) a meaningful component of treatment. A longitudinal study of 730 UM patients with liver metastasis showed median OS improving from 5.3 months (systemic-only) to 17.8 months when liver-directed treatment was incorporated.

ICI + liver-directed combination under clinical investigation
Preclinical

YAP/TAZ Pathway Inhibition

MD Anderson genetic data demonstrate that YAP activation alone is sufficient to initiate UM in vivo, and that dual YAP/TAZ + MAPK inhibition synergizes in suppressing oncogenic growth. No YAP/TAZ-targeting drug has yet progressed clinically in UM, representing a significant white space in the pipeline according to PatSnap patent landscape analysis.

YAP/TAZ + MAPK dual blockade is a rationally prioritized combination axis
PatSnap Eureka

Map every patent and paper in the UM pipeline

Access assignee landscapes, combination claims, and development stage tracking across all UM therapeutic modalities.

Explore UM Innovation Intelligence
Molecular Biology

The GNAQ/GNA11 Oncogenic Cascade and Key Vulnerabilities

Uveal melanoma is a molecularly distinct malignancy diverging sharply from cutaneous melanoma. The most frequently cited molecular driver is the mutually exclusive activation of GNAQ or GNA11—heterotrimeric G-protein alpha subunits—found in over 90% of UM tumors. As reviewed by Thomas Jefferson University, these mutations constitutively activate multiple downstream cascades including phospholipase C (PLCβ), protein kinase C (PKC), the MAPK/ERK axis, and the Hippo/YAP-TAZ pathway.

Less frequent upstream drivers include mutations in CYSLTR2 and PLCB4, which feed into the same linear cascade. University of California San Francisco demonstrated that CYSLTR2 → GNAQ/11 → PLCβ acts as a linear cascade driving PKC activation, which then bifurcates into PKC/RasGRP3/MAPK and FAK/YAP branches—with the MAPK branch identified as the essential proliferative effector.

Secondary genomic events that stratify metastatic risk include loss-of-function mutations in BAP1 (linked to monosomy of chromosome 3), SF3B1, and EIF1AX. BAP1 loss characterizes the high-risk metastatic class and may be tractable via histone deacetylase inhibitors. The NCI recognizes UM's distinct molecular profile as a key driver of its unique therapeutic challenges. HGF/MET signaling in the hepatic microenvironment further supports UM colonization and promotes treatment resistance, while IGF-1/IGF-1R and IRS-1/2 are overexpressed in UM tumors, with liver-borne IGF-1 potentially fueling metastatic growth.

Key Molecular Targets
GNAQ/GNA11
Mutated in >90% of UM; primary oncogenic driver
gp100/HLA-A*02:01
Tebentafusp target; present in ~40–50% of Western patients
YAP/TAZ
Sufficient to initiate UM in vivo; no clinical-stage inhibitor yet
HGF/MET
Hepatic microenvironment driver; resistance mechanism
BAP1
Loss = high metastatic risk; chromosome 3 monosomy marker
IRS-1/2
Overexpressed in UM; NT157 inhibitor shows in vivo activity
SAMMSON lncRNA
A UM-selective long non-coding RNA whose ASO-mediated knockdown impairs cell viability. mTOR inhibitor GDC-0349 enhances ASO delivery via lysosomal pathway modulation (Ghent University Hospital).
Data & Evidence

Clinical Evidence Signals Across the UM Pipeline

Quantitative signals from clinical trials, retrospective cohort studies, and phase 2 data illustrate where the evidence base is strongest in uveal melanoma drug development.

Liver-Directed Therapy: Median OS Improvement Across Cohorts (n=730)

Retrospective longitudinal data from Wills Eye Hospital / Thomas Jefferson University showing progressive OS improvement as liver-directed treatment was incorporated.

Liver-Directed Therapy Median OS: Cohort 1 (systemic only) 5.3 months, Cohort 2 13.6 months, Cohort 3 (liver-directed) 17.8 months. N=730 total UM patients with liver metastasis, 1971–2017. Bar chart comparing median metastasis-to-death overall survival across three historical cohorts of uveal melanoma patients with liver metastasis. Cohort 3, which incorporated liver-directed treatment, achieved 17.8 months median OS versus 5.3 months in Cohort 1 which relied predominantly on systemic therapy. Source: Thomas Jefferson University / Wills Eye Hospital retrospective study, via PatSnap Eureka. 20mo 15mo 10mo 5mo 0 5.3 mo Cohort 1 Systemic only 13.6 mo Cohort 2 Mixed approach 17.8 mo Cohort 3 Liver-directed

Tebentafusp Phase 2 Safety Profile: Most Common Adverse Events (n=127)

Frequency of adverse events in 127 previously treated metastatic UM patients; severity decreases after initial cycles (Memorial Sloan Kettering, 2022).

Tebentafusp Phase 2 Adverse Events (n=127): Rash 87%, Pyrexia 80%, Pruritus 67%. Severity decreases after initial cycles. Horizontal bar chart showing the three most common adverse events in the tebentafusp phase 2 trial at Memorial Sloan Kettering Cancer Center. Rash was most frequent at 87% of patients, followed by pyrexia at 80% and pruritus at 67%. Source: PatSnap Eureka literature analysis. 0% 25% 50% 75% 100% Rash 87% Pyrexia 80% Pruritus 67%

Search the full uveal melanoma patent and literature dataset in PatSnap Eureka

Run a UM Pipeline Search in Eureka
Clinical Trial & Study Signals

Documented Clinical Evidence in the UM Pipeline

Retrieved results contain direct clinical signals across multiple modalities, from FDA-approved agents to early-phase combination trials.

Agent / Modality Phase / Study Type Key Finding Institution Status
Tebentafusp Phase III RCT Improved OS vs. pembrolizumab, ipilimumab, or dacarbazine in first-line HLA-A*02:01+ metastatic UM Immunocore / Multi-center FDA Approved
Tebentafusp (Phase 2) Phase 2 (n=127) 1-year OS historically 37%; median OS 7.8 months in previously treated patients (NCT02570308) Memorial Sloan Kettering FDA Approved
Sotrastaurin + Alpelisib Phase Ib (n=25) Dose-escalation study of PKC inhibitor + PI3Kα inhibitor; maximum tolerated dose identification University of Miami Phase Ib/II
Liver-Directed Therapy Retrospective (n=730) Median OS improved from 5.3 months (systemic only) to 17.8 months with liver-directed treatment incorporation Wills Eye / Thomas Jefferson Clinical
Adjuvant Ipilimumab Phase I/II (n=10) 80% distant metastasis-free survival at 36 months in genomically high-risk primary UM MD Anderson Cancer Center Limited Efficacy
Pembrolizumab Expanded access (n=9) Median PFS 18 weeks; median OS 46 weeks; no objective responses per RECIST Belgian single-center Limited Efficacy
🔒
Unlock Full Clinical Evidence Table
Access glembatumumab vedotin Phase II data, ICI + liver-directed combination results, and additional clinical signals from the full PatSnap Eureka dataset.
Glembatumumab Ph. II ICI + liver-directed + more signals
Access Full Evidence Table →

Track every UM clinical signal as it emerges

PatSnap Eureka monitors patent filings, trial registrations, and literature publications across the full uveal melanoma pipeline in real time.

Monitor the UM Pipeline in Eureka
Combination Approaches

Convergent Combination Strategies in Uveal Melanoma

Retrieved results signal several convergent combination strategies driven by the inadequacy of single-agent approaches and the unique biology of hepatic metastatic spread.

🧬

PKC + MDM2 Inhibition

Both the Novartis patent portfolio (WO 2017/029588) and Institut Curie PDX data support this combination. PDX studies with AEB071 + MDM2 inhibitor showed tumor control, and Novartis IP formalizes this into a pharmaceutical combination claim for UM. The IL-jurisdiction patents are currently inactive, potentially signaling opportunity for new entrants.

💊

PKC + PI3K Inhibition

The University of Miami Phase Ib study (sotrastaurin + alpelisib) directly translates the preclinical observation that PI3K pathway inhibition enhances PKC inhibition in vivo into clinical evaluation. This acknowledges that single-agent PKC inhibition is insufficient for robust antitumor activity in metastatic UM.

🔬

CDK4/6 + MET Inhibition

Thomas Jefferson University demonstrated that the retinoblastoma pathway is deregulated in over 90% of UM despite rare RB1 mutations. HGF—enriched in hepatic sinusoids—decreases CDK4/6 inhibitor efficacy. Combining CDK4/6 inhibitor with a cMET inhibitor restored and enhanced growth suppression in human-HGF knock-in xenograft models, directly addressing the hepatic microenvironment.

🎯

YAP/TAZ + MAPK Dual Blockade

MD Anderson genetic data support that YAP activation cooperates with MAPK activation in UM progression and that dual inhibition is synergistic—establishing this as a rationally prioritized combination target axis. This approach may be more effective than MEK inhibition alone, warranting prioritized tool compound and IND-enabling work per PatSnap patent landscape analysis.

🔒
Unlock 2 More Combination Strategies
Access the mTOR + SAMMSON ASO delivery enhancement rationale and the University of Illinois PAC-1 + Entrectinib EP patent (2024) — the most recently filed active UM patent in this dataset.
mTOR + SAMMSON ASO PAC-1 + Entrectinib EP PARP + dacarbazine
Explore All Combination Strategies →
Assignee & Author Landscape

Who Is Driving Uveal Melanoma Innovation?

Innovation activity in this dataset is predominantly literature-driven (academic papers), with a smaller but strategically significant patent component. Immunocore Limited is the sole commercially oriented assignee with a product on the market, holding multiple retrieved papers describing tebentafusp's ImmTAC platform, mechanism, and clinical results.

Novartis AG is the primary commercial patent filer, holding two retrieved IL-jurisdiction filings (both currently inactive) covering MDM2 inhibitor + PKC pathway inhibitor combinations for UM. The inactive legal status of these filings may signal opportunity for new entrants in specific combination claims. PatSnap patent analytics can help identify white space in this combination IP landscape.

The Board of Trustees of the University of Illinois holds one active EP patent filing (published December 2024) covering PAC-1 + entrectinib synergy—the most recently filed active UM patent in this dataset, indicating active academic-to-commercial IP generation. Institut Curie contributes PDX-based PKC inhibitor combination studies, PARP inhibitor research, selumetinib combination studies, and SAMMSON ASO work. MD Anderson Cancer Center covers CDK4/6 inhibition, IRS-1/2 targeting, HGF/MET signaling, and glembatumumab vedotin clinical trial data. For a full competitive IP landscape, explore how PatSnap customers use Eureka for oncology pipeline intelligence. WIPO patent data underpins the global filing landscape analysis.

Key Organizations in This Dataset
Immunocore Limited
Sole commercial assignee with FDA-approved product (tebentafusp). ImmTAC platform originator.
Novartis AG
2 IL-jurisdiction patents (inactive) covering MDM2 + PKC combinations. PCT origin: WO 2017/029588.
University of Illinois
1 active EP patent (Dec 2024): PAC-1 + entrectinib synergy in GNAQ/GNA11 mutant UM.
Institut Curie / MD Anderson / Thomas Jefferson
Dominant academic contributors across PKC combinations, liver biology, and YAP/TAZ pathway research.
Frequently asked questions

Uveal Melanoma Drug Pipeline — key questions answered

Still have questions about the uveal melanoma pipeline? Let PatSnap Eureka answer them for you.

Ask Eureka About the UM Pipeline
PatSnap Eureka

Accelerate Your Uveal Melanoma Drug Discovery Intelligence

Join 18,000+ innovators already using PatSnap Eureka to track the UM pipeline, map assignee landscapes, and identify white space in combination therapy IP.

References

  1. Targeting Oncogenic Gαq/11 in Uveal Melanoma — Thomas Jefferson University, 2021 [Paper]
  2. Functional characterization of uveal melanoma oncogenes — University of California San Francisco, 2020 [Paper]
  3. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives — IRCCS Ospedale Policlinico San Martino, 2019 [Paper]
  4. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression — MD Anderson Cancer Center, 2019 [Paper]
  5. The Role of HGF/MET Signaling in Metastatic Uveal Melanoma — Thomas Jefferson University, 2021 [Paper]
  6. Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth — MD Anderson Cancer Center, 2022 [Paper]
  7. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma — Immunocore Limited, 2019 [Paper]
  8. Gp-100 as a Novel Therapeutic Target in Uveal Melanoma — Hospital Universitario La Paz / CIBERONC, 2021 [Paper]
  9. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma — Geisinger Enterprise Pharmacy, 2022 [Paper]
  10. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial — Memorial Sloan Kettering Cancer Center, 2022 [Paper]
  11. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling — Macquarie University, 2022 [Paper]
  12. Inhibitors for treating uveal melanoma (MDM2 + PKC combinations) — Novartis AG, 2018, IL [Patent]
  13. Inhibitors for treating uveal melanoma (MDM2 + PKC combinations, second filing) — Novartis AG, 2018, IL [Patent]
  14. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma — Institut Curie, 2016 [Paper]
  15. An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis — Wills Eye Hospital / Thomas Jefferson University, 2020 [Paper]
  16. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma — University Medical Center Hamburg-Eppendorf, 2021 [Paper]
  17. Combination therapy for the treatment of uveal melanoma (PAC-1 + Entrectinib) — The Board of Trustees of the University of Illinois, 2024, EP [Patent]
  18. National Institutes of Health (NIH) — Reference for Hippo/YAP-TAZ pathway biology
  19. National Cancer Institute (NCI) — Uveal melanoma molecular classification reference
  20. World Intellectual Property Organization (WIPO) — Global patent filing landscape for UM therapeutics

All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.

Ask PatSnap Eureka
Ask PatSnap Eureka
AI innovation intelligence · always on
Ask anything about the uveal melanoma drug pipeline.
PatSnap Eureka searches patents and research to answer instantly.
Try asking
Powered by PatSnap Eureka